NASDAQ:TLPH Talphera Q2 2026 Earnings Report $1.40 -0.03 (-2.10%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Talphera EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/ATalphera Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATalphera Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Talphera Earnings HeadlinesTalphera (NASDAQ:TLPH) Raised to Hold at Wall Street ZenAugust 8 at 1:13 AM | americanbankingnews.comTalphera (TLPH) Expected to Announce Earnings on ThursdayAugust 6, 2026 | americanbankingnews.comBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.August 10 at 1:00 AM | Golden Portfolio (Ad)Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026August 5, 2026 | prnewswire.comTalphera (TLPH) CEO Angotti buys $85k in sharesMay 21, 2026 | investing.comTalphera Earnings Call Highlights NEPHRO Trial MomentumMay 19, 2026 | tipranks.comSee More Talphera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Talphera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Talphera and other key companies, straight to your email. Email Address About TalpheraTalphera (NASDAQ:TLPH), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.View Talphera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat5 Stocks the Market Rewarded After Strong Earnings ResultsQuantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of WarCloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusIs Monster Beverage’s Best-Case Scenario Already Priced Into the Stock? Upcoming Earnings SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
